The Endocrinology Society has announced that the Apitope paper published in Endocrinology entitled “Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice” has been featured in its Thematic issue on immuno endocrinology. The paper was recognised for its high Altmetric Attention Score and Featured Article designations.
The Endocrine Society said “We appreciate your cutting-edge, influential contributions to the endocrine community and are delighted to promote it in our thematic collection”
Apitope's Chief Executive Officer Hayley French and Chief Research Officer Lotta Jansson will be attending JP Morgan 38th Annual Healthcare Conference 13-16 January 2020 in San Francisco.
Please contact Hayley.French@apitope.com or Lotta.Jansson@apitope.com for further information
Apitope’s Antigen specific immunotherapy for Graves’ disease features in the October 2019 edition of the British Thyroid Foundation Newsletter (BTF) and the article is also available on the BTF website by following this link: https://www.btf-thyroid.org/research-news-graves-disease
HASSELT, Belgium, and CHEPSTOW, UK, 13 September 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that the first in human clinical trial for the treatment of Graves’ disease funded by the European Union (DAVIAD) has been published as a “Success Story” on the European Union website. The article entitled ‘ New treatment on the horizon for Graves' disease’ can be viewed in the following link: